宁波三星医疗电气股份有限公司（以下简称"公司"）于 2025 年 10 月 29 日召开第六届董事会第二十六次会议，审议通过了《关于公司变更注册资本、修 订<公司章程>并办理工商变更登记的议案》。 证券代码：601567 证券简称：三星医疗 公告编号：临 2025-083 宁波三星医疗电气股份有限公司 关于公司变更注册资本、修订《公司章程》并办理工商变更 登记的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 除上述条款修订外，《公司章程》其他条款不变。根据公司 2021 年第二次 临时股东大会、2022 年第一次临时股东大会的相关授权，本次变更注册资本及 修订《公司章程》的议案无需提交公司股东会审议，后续公司将申请办理相关工 商变更登记手续，最终以宁波市市场监督管理局的登记结果为准。修订后的《公 司章程》详见同日披露于上海证券交易所网站（www.sse.com.cn）的《宁波三星 医疗电气股份有限公司章程》（2025 年 10 月修订）。 一、注册资本变更情况 特此公告。 宁波三星医疗电气股份有限公司 董事会 二〇二五年 ...

证券代码：601567 证券简称：三星医疗 公告编号：临 2025-085 注册资本：1,405,251,200 元 成立日期：2007 年 02 月 01 日 公司名称：宁波三星医疗电气股份有限公司 公司类型：其他股份有限公司（上市） 统一社会信用代码：9133020079603386X0 住所：浙江省宁波市鄞州工业园区（宁波市鄞州区姜山镇） 法定代表人：沈国英 宁波三星医疗电气股份有限公司 关于完成工商变更登记的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 宁波三星医疗电气股份有限公司（以下简称"公司"）分别于 2025 年 5 月 28 日、2025 年 6 月 13 日、2025 年 8 月 21 日、2025 年 9 月 8 日召开第六届董事 会第二十三次会议、2025 年第一次临时股东会、第六届董事会第二十五次会议、 2025 年第二次临时股东会，审议通过了《关于变更部分回购股份用途为注销并 减少公司注册资本的议案》、《关于公司取消监事会、修订<公司章程>并办理工 商变更登记的议案》。具体详见公司于 202 ...

证券代码：601567 证券简称：三星医疗 公告编号：临 2025-082 宁波三星医疗电气股份有限公司 第六届董事会第二十六次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 宁波三星医疗电气股份有限公司（以下简称"公司"）于 2025 年 10 月 17 日 以电话、传真、邮件等方式发出召开第六届董事会第二十六次会议的通知，会议 于 2025 年 10 月 29 日在公司会议室以现场结合通讯方式召开。本次会议应到董 事 9 人，实到董事 9 人。会议由董事长沈国英女士主持，公司高级管理人员列席 了会议。会议的召集和召开符合《中华人民共和国公司法》和《宁波三星医疗电 气股份有限公司章程》等法律、法规及规范性文件的有关规定。经与会董事认真 审议并表决，通过了以下议案，形成决议如下： 一、审议通过了关于 2025 年第三季度报告的议案 详见公司披露于上海证券交易所网站（www.sse.com.cn）的《三星医疗 2025 年第三季度报告》。 宁波三星医疗电气股份有限公司 董事会 二〇二五年十月三十日 表决结果：9 票 ...

Financial Performance - The company's operating revenue for Q3 2025 was ¥3,107,668,549.87, a decrease of 9.56% compared to the same period last year[3] - Total profit for the quarter was ¥378,801,775.05, down 50.10% year-over-year[3] - Net profit attributable to shareholders was ¥298,100,911.93, reflecting a decline of 55.22% compared to the previous year[3] - The net profit after deducting non-recurring gains and losses was ¥143,825,308.45, a significant drop of 78.54% year-over-year[3] - The basic earnings per share for the quarter was ¥0.21, down 55.03% from the same period last year[3] - Net profit for the first three quarters of 2025 was CNY 1,506,796,242.67, a decrease of 17.3% from CNY 1,822,779,409.65 in 2024[20] - Earnings per share (EPS) for the first three quarters of 2025 was CNY 1.08, down from CNY 1.29 in the same period of 2024[22] - The company reported a total comprehensive income of ¥431,586,311.37 for the first three quarters of 2025, down from ¥539,637,737.89 in the same period of 2024[30] Cash Flow - The net cash flow from operating activities was ¥517,267,564.70, a decrease of 32.73% compared to the previous year[3] - In the first three quarters of 2025, the net cash flow from operating activities was ¥458,011,287.76, a decrease of 55.5% compared to ¥1,029,211,957.25 in the same period of 2024[24] - Total cash inflow from operating activities for the first three quarters of 2025 was ¥10,404,489,143.43, up 6.3% from ¥9,788,478,776.79 in 2024[24] - The cash outflow from operating activities increased to ¥9,946,477,855.67 in 2025, compared to ¥8,759,266,819.54 in 2024, reflecting a rise of 13.5%[24] - The company experienced a net cash outflow from financing activities of ¥1,721,170,096.41 in the first three quarters of 2025, compared to a net outflow of ¥2,710,951,807.47 in the same period of 2024[33] Assets and Liabilities - Total assets at the end of the quarter were ¥24,156,894,322.04, a decrease of 1.31% from the end of the previous year[4] - The total assets as of September 30, 2025, reached ¥14,321,788,079.64, an increase of 10.1% from ¥12,932,806,743.68 at the end of 2024[26] - The company's total liabilities increased to ¥6,536,169,593.84 in 2025, compared to ¥4,390,923,329.33 in 2024, marking a rise of 48.9%[27] - The total liabilities decreased from CNY 12,202,548,432.10 in the previous year to CNY 11,490,388,612.32, a reduction of approximately 5.8%[16] - The total equity decreased to ¥6,785,618,485.80 in 2025 from ¥6,541,883,000.00 in 2024, indicating a decline of 3.7%[27] - The total equity increased from CNY 12,273,938,154.83 to CNY 12,666,505,709.71, reflecting a growth of about 3.2%[16] Orders and Production - Total orders on hand reached RMB 17.914 billion, a year-on-year increase of 14.69%[13] - Overseas distribution orders on hand amounted to RMB 2.169 billion, growing by 125.45% year-on-year[13] - The company plans to establish a new production base in Kenya by July 2025 to support business expansion in Africa[13] Research and Development - Research and development expenses for the first three quarters were CNY 421,981,091.96, slightly up from CNY 413,019,007.29 in the previous year[19] - Research and development expenses for the first three quarters of 2025 were ¥96,734,878.23, a decrease of 4.9% compared to ¥101,240,517.46 in the first three quarters of 2024[29] Other Financial Metrics - The weighted average return on equity was 2.45%, a decrease of 12.47% from the end of the previous year[4] - Non-recurring gains and losses for the quarter totaled ¥154,275,603.48, down from ¥248,293,933.48 in the previous year[6] - Financial expenses showed a significant improvement, with a net income of CNY -108,671,097.00 compared to CNY 77,987,744.96 in the previous year[19] - The company reported an investment income of CNY 178,574,515.32, which is a slight increase from CNY 177,637,485.16 in the same period last year[20] - Other comprehensive income after tax for the first three quarters of 2025 was -¥57,086,153.27, compared to -¥7,714,780.00 in the same period of 2024[30]

章程 2025 年 10 月 | 第一章 | 总 则 2 | | | --- | --- | --- | | 第二章 | 经营宗旨和范围 | 3 | | 第三章 | 股 份 4 | | | 第一节 | 股份发行 | 4 | | 第二节 | 股份增减和回购 | 5 | | 第三节 | 股份转让 | 6 | | 第四章 | 股东和股东会 | 7 | | 第一节 | 股东的一般规定 | 7 | | 第二节 | 控股股东和实际控制人 9 | | | 第三节 | 股东会的一般规定 | 10 | | 第四节 | 股东会的召集 | 13 | | 第五节 | 股东会的提案与通知 | 15 | | 第六节 | 股东会的召开 | 16 | | 第七节 | 股东会的表决和决议 | 19 | | 第五章 | 董事和董事会 | 23 | | 第一节 | 董事的一般规定 | 23 | | 第二节 | 董事会 | 26 | | 第三节 | 独立董事 30 | | | 第四节 | 董事会专门委员会 | 33 | | 第六章 | 总经理（总裁）及其他高级管理人员 | 34 | | 第七章 | 财务会计制度、利润分配和审计 | 36 | | 第 ...

Core Insights - Samsung Medical reported a third-quarter revenue of 3.108 billion, a year-on-year decrease of 9.56% [1] - The net profit for the third quarter was 298 million, reflecting a year-on-year decline of 55.22% [1] - For the first three quarters, the total revenue reached 11.08 billion, showing a year-on-year growth of 6.19% [1] - The net profit for the first three quarters was 1.528 billion, which represents a year-on-year decrease of 15.85% [1]

Investment Rating - The report maintains a "Buy" rating for multiple companies in the energy and power equipment sector, including Ningde Times, Pinggao Electric, Guoneng Rixin, Sany Renewable Energy, and others [4][7][8]. Core Insights - The report emphasizes the importance of a comprehensive green transition in China's economy, driven by goals of carbon peak and carbon neutrality, with a focus on developing a new energy system [1][2]. - The dual control of carbon emissions is expected to expand the demand for green electricity, with policies promoting both carbon market management and mandatory green electricity consumption [2][3]. - The energy sector's green and low-carbon transformation is identified as a critical area for achieving overall green transition goals, with a significant portion of new electricity demand expected to be met by clean energy sources by the end of the 14th Five-Year Plan [3]. Summary by Sections Section 1: Industry Overview - The report highlights the acceleration of green transformation in the economy, with key measures including the establishment of a dual control system for carbon emissions and the promotion of green energy transition [1][2]. Section 2: Company Recommendations - **Ningde Times (300750 CH)**: Target price raised to 566.18 CNY, with a strong outlook on electric vehicle and energy storage markets [9][10]. - **Pinggao Electric (600312 CH)**: Target price set at 22.80 CNY, benefiting from strong domestic bidding for power transmission and transformation equipment [11]. - **Guoneng Rixin (301162 CH)**: Target price of 73.54 CNY, with significant growth in service stations and customer retention [12]. - **Sany Renewable Energy (688349 CH)**: Target price increased to 38.01 CNY, with expectations of improved profitability in wind turbine sales [14]. - **Siyuan Electric (002028 CH)**: Target price raised to 147.90 CNY, driven by strong growth in overseas orders and data center demand [14]. - **Sungrow Power Supply (300274 CH)**: Target price set at 195.40 CNY, with a focus on energy storage and international expansion [14]. - **Oriental Electronics (000682 CH)**: Target price of 13.86 CNY, with steady growth in core business and new energy projects [14]. - **China Western Power (601179 CH)**: Target price set at 8.25 CNY, with a stable growth outlook in power transmission equipment [14]. - **Guodian NARI Technology (600406 CH)**: Target price of 26.00 CNY, benefiting from new power system construction [14].

证券代码：601567 证券简称：三星医疗 公告编号：临2025-081 宁波三星医疗电气股份有限公司 关于为子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 | 对外担保逾期的累计金额（万元） | 0 | | --- | --- | | 截至本公告日上市公司及其控股 子公司对外担保总额（万元） | 975,350.00 | | 对外担保总额占上市公司最近一 期经审计净资产的比例（%） | 80.73% | | 100% 特别风险提示（如有请勾选） | □对外担保总额超过最近一期经审计净资产 | | | 担保金额超过上市公司最近一期经审计净 | | 资产 | 50% | | | □对合并报表外单位担保金额达到或超过最 | | | 近一期经审计净资产 30%的情况下 | | | 对资产负债率超过 70%的单位提供担保 | | 其他风险提示（如有） 无 | | 注：表中截至本公告日上市公司及其控股子公司对外担保总额，包含年度已批准的担 保额度内尚未使用额度与担保实际发生余额之和，并非公司实际发生的担保余 ...

Core Viewpoint - Samsung Medical achieved overseas revenue of 1.495 billion yuan in the first half of the year, representing a year-on-year growth of 51% [1] Group 1: Overseas Expansion - The company made significant breakthroughs in key overseas markets including Europe, the Middle East, and Latin America, with initial orders secured in Saudi Arabia, Mexico, Greece, and Brazil [1] - In the first half of 2025, the company also secured initial orders in Hungary, Romania, and Kyrgyzstan [1] - The company is focusing on high-end products and emerging markets, strengthening its presence in North America and Africa [1] Group 2: Local Operations and Support - The company is enhancing its localized operations by establishing a new sales company in Hungary, which will provide strong support for its overseas distribution business [1] Group 3: Order Backlog - The total order backlog for the company reached 17.632 billion yuan, reflecting a year-on-year increase of 18.39% [1] - The overseas distribution order backlog amounted to 2.182 billion yuan, showing a substantial year-on-year growth of 123.96% [1] Group 4: Investment Rating - Given the high growth in overseas orders and the company's leading position domestically, an investment rating of "Buy" has been assigned [1]

Core Viewpoint - Samsung Medical achieved significant growth in overseas revenue, indicating strong market expansion and order growth, particularly in Europe and emerging markets [1] Group 1: Overseas Revenue Growth - The company reported overseas revenue of 1.495 billion yuan in the first half of the year, representing a year-on-year increase of 51% [1] - Key breakthroughs in overseas distribution were made in Europe, the Middle East, and Latin America, with initial orders secured in Hungary, Romania, and Kyrgyzstan in the first half of 2025 [1] Group 2: Order Backlog - The total order backlog for the company reached 17.632 billion yuan, reflecting a year-on-year growth of 18.39% [1] - The overseas distribution order backlog amounted to 2.182 billion yuan, showing a substantial year-on-year increase of 123.96% [1] Group 3: Strategic Initiatives - The company is focusing on high-end markets and emerging regions, enhancing its presence in North America and Africa [1] - A new sales company was established in Hungary to support the expansion of overseas distribution business [1]